Company: PSTV
Filing Date: 2025-08-12
Form Type: S-1
Source: 0001193125-25-178940
Chunk: 23

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-08-12
Form: S-1
Chunk 23
---
 wish to effect such sales. However, we have the right to control the timing and amount of any sales of our common stock to Lincoln Park and the Purchase Agreement may be terminated by us at any time without any cost to us. Pursuant to the terms of the Purchase Agreement, we have the right, but not the obligation, from time to time to direct Lincoln Park to purchase up to $50.0 million of our common stock, of which $47.2 million remains 12

to be purchased under the Purchase Agreement (exclusive of the Initial Commitment Shares and Additional Commitment Shares, if applicable, issuable to Lincoln Park), of which initially $25 million and if the full $25 million is purchased, then immediately and automatically up to an additional $25 million aggregate gross proceeds. Depending on the price per share at which we sell our common stock to Lincoln Park pursuant to the Purchase Agreement, we may need to sell to Lincoln Park more shares of our common stock than are offered under this prospectus in order to receive aggregate gross proceeds equal to the approximately $47.2 million remaining balance of the $50.0 million total commitment available to us under the Purchase Agreement. If we choose to do so, we must again register for resale under the Securities Act such additional shares of our common stock, which could cause additional substantial dilution to our stockholders. The number of shares ultimately offered for resale by Lincoln Park under this prospectus is dependent upon the number of shares we direct Lincoln Park to purchase under the Purchase Agreement. On August 7, 2025, we received the stockholder approval required before issuing more than the Exchange Cap limit of 10,194,593 shares (including the Initial Commitment Shares and Additional Commitment Shares, if applicable), which represents 19.99% of our outstanding shares immediately prior to the execution of the Purchase Agreement. We have filed the registration statement that includes this prospectus so that we may issue to Lincoln Park up to 33,000,000 shares of our common stock, consisting of up to 31,387,097 shares of our common stock from time to time from and after the date of this prospectus through sales under the Purchase Agreement and 1,612,903 shares of our common stock that are the Initial Commitment Shares, for which we received no cash consideration. The following table sets forth the amount of gross proceeds we may receive from Lincoln Park from our sale of up to 31,387,097 shares of our common stock that we may issue and sell to